<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01258673</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FHC-CT-301</org_study_id>
    <nct_id>NCT01258673</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy</brief_title>
  <official_title>A Randomized, Double-blind, Multicenter Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy in Comparison With Fimasartan Monotherapy for Essential Hypertension Patients Not Controlled by Fimasartan 60mg(Phase 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DongGuk University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cheil General Hospital and Womenâ€™s Healthcare Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ilsan-Paik Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyung Hee University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antihypertensive efficacy and safety of
      Fimasartan/Hydrochlorothiazide combination 60/12.5mg~120/12.5mg in patients with essential
      hypertension who are not controlled by fimasartan 60mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>4week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure / Diastolic Blood Pressure</measure>
    <time_frame>4week, 8week / 8week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">263</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Fimasartan/HCTZ combination group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan/HCTZ combination</intervention_name>
    <description>Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg</description>
    <arm_group_label>Fimasartan/HCTZ combination group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan</intervention_name>
    <description>Fimasartan 60mg, 120mg</description>
    <arm_group_label>Fimasartan group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female outpatients 18 years of age and older

          -  Patients with antihypertensive agents at screening: DBP&lt;110mmHg or Patients without
             antihypertensive agents at screening: DBP 90mmHg~120mmHg

          -  Subjects who agree to participate in this sudy and give written informed consent

          -  Subjects considered to understand the study, be cooperative, and able to be
             followed-up until the end of the study

          -  Patients with not controlled blood pressure at baseline visit, by fimasartan 60mg
             4weeks treatment, DBP 90mmHg~109mmHg and SBP&lt;180mmHg

        Exclusion Criteria:

          -  The sitting DBP is more than 120mmHg or severe hypertensive patient with sitting
             systolic blood pressure over 200mmHg Patients with secondary hypertension

          -  Patients who are measured the mean difference of mean blood pressure under SiDBP
             10mmHg or SiSBP 20mmHg at screening or baseline visit

          -  Patients with severe renal(Creatinine more 1.5 times than upper limit of normal),
             gastrointestinal, hematological or hepatic(AST, ALT more 2 twice more than upper limit
             of normal)disease etc. which might affect absorption, disposition, metabolism or
             excretion of the drug

          -  Patients with postural hypotension

          -  Patients with sever insulin dependent diabetes mellitus or uncontrolled diabetes
             mellitus(HbA1c&gt;9%, regimen change of oral hypoglycemic agents within 12weeks, treated
             insulin before screening)

          -  Patients with a history of myocardial infarction, severe coronary artery disease or
             clinically significant heart failure or valvular defect in last 6 months

          -  Patients with consumptive disease, autoimmune disease, connective tissue disease

          -  Patients with a history of type B or C hepatitis(include carrier)

          -  Patients with HIV or hepatitis

          -  Patients with clinically significant laboratory abnormality

          -  Patients receiving any drugs known to affect blood pressure or medical treatments that
             can influence the blood pressure

          -  Patients with allergy or contraindication to any angiotensin II receptor antagonists

          -  Female of childbearing potential who does not undergo hysterectomy or is not
             post-menopausal

          -  Patients judged to have a history of alcohol or drug abuse by the investigator

          -  Patients participated other clinical trial 12 weeks before Screening - Patients judged
             to be inappropriate for this study by the investigator with other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital, Bundang</name>
      <address>
        <city>Sungnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2010</study_first_submitted>
  <study_first_submitted_qc>December 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2010</study_first_posted>
  <last_update_submitted>January 2, 2012</last_update_submitted>
  <last_update_submitted_qc>January 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fimasartan</keyword>
  <keyword>Fimasartan/Hydrochlorothiazide combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

